HomeCompareWCIG vs ABBV

WCIG vs ABBV: Dividend Comparison 2026

WCIG yields 48899.76% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 WCIG wins by $3.836243142814248e+23M in total portfolio value
10 years
WCIG
WCIG
● Live price
48899.76%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3.836243142814248e+23M
Annual income
$382,087,244,343,937,260,000,000,000,000.00
Full WCIG calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — WCIG vs ABBV

📍 WCIG pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodWCIGABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, WCIG + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
WCIG pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

WCIG
Annual income on $10K today (after 15% tax)
$4,156,479.22/yr
After 10yr DRIP, annual income (after tax)
$324,774,157,692,346,700,000,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, WCIG beats the other by $324,774,157,692,346,700,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of WCIG + ABBV for your $10,000?

WCIG: 50%ABBV: 50%
100% ABBV50/50100% WCIG
Portfolio after 10yr
$1.918121571407124e+23M
Annual income
$191,043,622,171,968,630,000,000,000,000.00/yr
Blended yield
99.60%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

WCIG
No analyst data
Altman Z
-496.8
Piotroski
1/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

WCIG buys
0
ABBV buys
0
No recent congressional trades found for WCIG or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricWCIGABBV
Forward yield48899.76%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$3.836243142814248e+23M$102.3K
Annual income after 10y$382,087,244,343,937,260,000,000,000,000.00$24,771.77
Total dividends collected$3.835234051496043e+23M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: WCIG vs ABBV ($10,000, DRIP)

YearWCIG PortfolioWCIG Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$4,900,676$4,889,975.55$11,550$430.00+$4.89MWCIG
2$2,244,887,052$2,239,643,328.90$13,472$627.96+$2244.87MWCIG
3$961,214,396,668$958,812,367,522.49$15,906$926.08+$961214.38MWCIG
4$384,714,206,610,733$383,685,707,206,298.20$19,071$1,382.55+$384714206.59MWCIG
5$143,930,776,831,875,630$143,519,132,630,802,140.00$23,302$2,095.81+$143930776831.85MWCIG
6$50,335,255,165,183,440,000$50,181,249,233,973,340,000.00$29,150$3,237.93+$50335255165183.41MWCIG
7$16,455,084,083,975,364,000,000$16,401,225,360,948,620,000,000.00$37,536$5,121.41+$16455084083975364.00MWCIG
8$5,028,560,175,170,294,000,000,000$5,010,953,235,200,440,000,000,000.00$50,079$8,338.38+$5028560175170293760.00MWCIG
9$1,436,513,960,268,740,000,000,000,000$1,431,133,400,881,308,000,000,000,000.00$69,753$14,065.80+$1.43651396026874e+21MWCIG
10$383,624,314,281,424,800,000,000,000,000$382,087,244,343,937,260,000,000,000,000.00$102,337$24,771.77+$3.836243142814248e+23MWCIG

WCIG vs ABBV: Complete Analysis 2026

WCIGStock

Wee-Cig International Corporation, a holding and acquisition company, primarily focus on identifying tech companies in emerging markets. The company is scouring the technology landscape to find the investment opportunities. Wee-Cig International Corporation was incorporated in 1999 and is based in Las Vegas, Nevada.

Full WCIG Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this WCIG vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

WCIG vs SCHDWCIG vs JEPIWCIG vs OWCIG vs KOWCIG vs MAINWCIG vs JNJWCIG vs MRKWCIG vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.